Skip to Main Content
Our Commitment to Diversity
Alex Rolband

Alex Rolband is a patent technical specialist in the firm’s IP Procurement and Portfolio Management practice. Prior to joining the firm, Alex was a postdoctoral research associate at North Carolina State University. Alex received his Ph.D. in Nanoscale Science from the University of North Carolina at Charlotte. His research background as a biophysical chemist focused heavily on the design and characterization of therapeutic nucleic acids for applications as gene therapies, antibiotics, and anticoagulants. Alex also served 8 years in the North Carolina Army National Guard as an artillery observer and was a member of the Honor Guard.

  • Member, American Chemical Society, 2016-Present
  • Speaker, “Investigating the mechanism of Nsa1 removal from the pre-60s ribosomal subunit by Rix7 through single-molecule FRET,” SERMACS 2023, October 2023.
  • Speaker, “Assessing the Biological Activities of DNA-Templated Silver Nanoclusters,” Complex Matter and Biophysics Seminar, September 2023.
  • Speaker, “SAXS for NANPs: Advancing the Structural Characterization of Ribonucleic Acid Nanoparticles Through Small-Angle X-ray Scattering,” ASBMB 2023, March 2023.
  • Speaker, “Enhanced Structural Characterization of Multi-stranded Nucleic Acid Nanoparticles,” SERMACS 2021, November 2021.
  • Speaker, “Using RNA Nanoring Scaffolds to Modulate the Fluorescent Properties of Silver Nanoclusters, 22nd Rustbelt RNA Meeting, October 2020.
  • Speaker, “Recent Uses of SAXS in Probing Nucleic Acid Nanotechnology Structure and Function,” Smart Materials Programmed to Operate in Living Systems, May 2020.
  • Co-Author, “Demonstrating the Synthesis and Antibacterial Properties of Nanostructured Silver,” Journal of Chemical Education, 2023.
  • Co-Author, “Optical, structural and antibacterial properties of silver nanoparticles and DNA-templated silver nanoclusters,” Nanomedicine, 2023.
  • Co-Author, “Expanding Structural Space for Immunomodulatory Nucleic Acid Nanoparticles via Spatial Arrangement of Their Therapeutic Moieties,” Advanced Functional Materials, 2022.
  • Co-Author, “Locking and Unlocking Thrombin Function Using Immunoquiescent Nucleic Acid Nanoparticles with Regulated Retention In Vivo,” Nano Letters, 2022.
  • Co-Author, “Biomotors, viral assembly, and RNA nanobiotechnology: Current achievements and future directions,” Computational and Structural Biotechnology Journal, 2022.
  • Co-Author, “DNA-Templated Fluorescent Silver Nanoclusters Inhibit Bacterial Growth While Being Non-Toxic to Mammalian Cells,” Molecules, 2021.
  • Co-Author, “Challenges to optimizing RNA nanostructures for large scale production and controlled therapeutic properties,” Nanomedicine, Future Medicine, 2020.
  • Co-Author, “Tuning properties of silver nanoclusters with RNA nanoring assemblies,” Nanoscale, 2020.
  • Co-Author, “Small-Angle Scattering as a Structural Probe for Nucleic Acid Nanoparticles (NANPs) in a Dynamic Solution Environment,” Nanomaterials, MDPI, 2019.
  • Co-Author, “The Natural Versatility of RNA,” RNA Nanotechnology and Therapeutics, 2022.
  • Co-Author, “Light Scattering Techniques for Characterization of NANPs and Their Formulations,” RNA Nanotechnology and Therapeutics, 2022.
  • Co-Author, “Anticoagulant Activity of Nucleic Acid Nanoparticles (NANPs) Assessed by Thrombin Generation Dynamics on a Fully Automated System,” Methods in Molecular Biology, 2023.
  • Co-Author, “Synthesis of DNA-Templated Silver Nanoclusters and the Characterization of Their Optical Properties and Biological Activity,” Methods in Molecular Biology, 2023.
  • Co-Author, “Aptamer Conjugated RNA/DNA Hybrid Nanostructures Designed for Efficient Regulation of Blood Coagulation,” Methods in Molecular Biology, 2023.
  • Co-Author, “Structural Characterization of Nucleic Acid Nanoparticles Using SAXS and SAXS-Driven MD,” Methods in Molecular Biology, 2023.
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel